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Activated neutrophil fluorescent 
imaging technique for human lungs
Thomas H. Craven1,2*, Tashfeen Walton3, Ahsan R. Akram1, Emma Scholefield1, 
Neil McDonald1, Adam D.L. Marshall1, Duncan C. Humphries1, Bethany Mills1, 
Thane A. Campbell1, Annya Bruce1, Joanne Mair1, James W. Dear4, David E. Newby4, 
Adam T. Hill1, Timothy S. Walsh2, Chris Haslett1 & Kevin Dhaliwal1
Neutrophil activation is an integral process to acute inflammation and is associated with adverse 
clinical sequelae. Identification of neutrophil activation in real time in the lungs of patients may permit 
biological stratification of patients in otherwise heterogenous cohorts typically defined by clinical 
criteria. No methods for identifying neutrophil activation in real time in the lungs of patients currently 
exist. We developed a bespoke molecular imaging probe targeting three characteristic signatures of 
neutrophil activation: pinocytosis, phagosomal alkalinisation, and human neutrophil elastase (HNE) 
activity. The probe functioned as designed in vitro and ex vivo. We evaluated optical endomicroscopy 
imaging of neutrophil activity using the probe in real-time at the bedside of healthy volunteers, 
patients with bronchiectasis, and critically unwell mechanically ventilated patients. We detected a 
range of imaging responses in vivo reflecting heterogeneity of condition and severity. We corroborated 
optical signal was due to probe function and neutrophil activation.
Neutrophils and neutrophil activation are a hallmark of  inflammation1–7. Despite having a pivotal role in host 
defense, uncontrolled neutrophil activity leads to excessive tissue injury through proteinases, cytokines and 
reactive oxygen  species8,9 and the induction of apoptosis in epithelial  cells10. Phenotypic analysis of peripheral 
blood neutrophils, whilst useful, does not reflect the post-migratory phenotype of tissue neutrophils in vivo 
in situ. Currently, there are no sensitive and specific methods to detect in situ neutrophil activation in real-time.
Many diseases are characterised by excessive neutrophil activity. In the lung these would include acute res-
piratory distress syndrome (ARDS)11,12, community and ventilator associated  pneumonia3, chronic obstructive 
pulmonary  disease13, and  bronchiectasis14. Detecting and monitoring real-time neutrophil activity in vivo in situ 
may offer useful insights into disease pathology. Furthermore, the ability to detect neutrophil activation at the 
bedside in mechanically-ventilated (MV) patients offers a potential clinical tool to aid stratification and thera-
peutic targeting in ARDS and its risk groups. In airway and parenchymal diseases characterised by neutrophilic 
inflammation and damage, we hypothesized that the combination of a specific optical SmartProbe and bedside 
optical endomicroscopy (OEM) would provide an in situ indicator of alveolar neutrophil activation.
Enzymatic activity is common target for investigation and lends itself to investigation through optical tech-
niques. Neutrophil elastase is the most abundant enzyme released from activating neutrophils, and elastase 
specific probes have been used to examine the spatiotemporal function of elastase on the surface of  cells15,16 
and  intracellularly17, and during in vivo murine modeling of lung  injury18. To date, no imaging probe has been 
translated for in vivo human imaging, but with the development of fibre-based optical endomicroscopy there 
have been increasing deployments of optical imaging for lung applications at the  bedside19–22. We previously 
reported a multi-branched compound for fluorescent detection of neutrophil  elastase23 and have modified that 
structure to generate a bespoke chemical SmartProbe for the detection of activated neutrophils that would be 
suitable for clinical deployment.
This Neutrophil Activation Probe (NAP) consists of three internally quenched fluorescein moieties, each con-
jugated to an optimized peptide sequence, and all attached to a tri-branched multivalent scaffold. It was designed 
to amplify fluorescent emission and ‘tag’ neutrophils in response to three processes in the pathway of neutrophil 
activation; (i) enhanced pinocytosis, (ii) progressive alkalinization of the phagosome, and (iii) increased human 
neutrophil elastase (HNE) activity. Together, the targeting of these augmented metabolic processes makes the 
generated cellular fluorescent signal specific to activated neutrophils.
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Results
NAP is a sensor of human neutrophil elastase activity and pH. NAP consists of a six-amino acid 
(Glu–Glu–Ile–Nle–Arg–Arg) sequence on a tri-branched scaffold (Fig. 1A) with a λex of 488 nm (Fig. 1B) ensur-
ing compatibility with clinical OEM systems that employ the 488 nm argon ion-excitation source. When incu-
bated in the presence of physiologically and pathologically relevant concentrations of  HNE3, there was a rapid 
dequenching (Fig. 1C) with an increase in fluorescence of nearly 350% compared to the resting state. Cleavage 
was also completely abrogated in the presence of Sivelestat, a specific inhibitor of  HNE24. NAP acted as a pH 
sensor, in keeping with a multitude of fluorescein protolytic forms, but with a serendipitous steepening of the 
fluorescent response as pH increases over the physiologically relevant range compared to the emission spectra of 
carboxyfluorescein (Fig. 1D), with the pH profile modulated by the tri-branched nature of the construct, thereby 
altering the pKa values expected for carboxyfluorescein.
Figure 1.  (A) Chemical structure of the NAP Smartprobe; (B) the absorbance spectra (with pH) and the 
emission spectra for NAP in phosphate buffered saline at pH 7.4 (5 µM, λex = 430 nm). Cleaved in the presence 
of elastase, which liberates carboxyfluorescein from the dendrimer backbone, releases internal quenching 
mechanism and permits fluorescence. (C) Time course of fluorescence dequenching in the presence of purified 
HNE. Coloured lines represent control conditions (NAP in the absence of HNE, blue line; NAP and 100 nM 
HNE in the presence of the specific HNE inhibitor Sivelestat (100 µM), red line; NAP and 50 nM or 100 nM 
proteinase 3, green lines). Mean point estimate (+ SEM) from three independent experiments. Modest cleavage 
is shown with supraphysiological concentrations of proteinase 3, an alternative neutrophil specific serine 
protease. (D) Change in fluorescence with pH (freshly made up pH buffer). NAP (5 µM) shows an increase in 
fluorescence as pH increases (black circles). There is a steepening of the curve around physiologically relevant 
pH values. At equivalent concentrations of carboxyfluorescein (15 µM) there is the expected increase in 
fluorescence as  H+ concentration falls (grey triangles). Mean point estimate (± SD, n = 1, in triplicate). (Note the 
concentration of NAP is 5 µM, but it carries 3 copies of carboxyfluorescein).
3
Vol.:(0123456789)
Scientific Reports |          (2021) 11:976  | https://doi.org/10.1038/s41598-020-80083-w
www.nature.com/scientificreports/
Enhanced cellular fluorescent signal is specific to activated neutrophils. Confocal microscopy 
was used to characterise the imaging properties of NAP in vitro. Isolated neutrophils, treated with the calcium 
ionophore A23187 (10 µM, in order to increase intracellular calcium and induce a variety of secondary acti-
vation effects such as degranulation and superoxide production) in the presence of NAP (5 µM), showed an 
increase in intracellular punctate fluorescence compared to untreated neutrophils (Fig. 2A and Supplementary 
Fig. S1), while human alveolar macrophages retrieved from broncho-alveolar lavage fluid (BALF) and exposed 
to NAP ex vivo showed no signal when activated (Supplementary Fig. S2). Treated and untreated mixed leuco-
cyte populations were analysed by flow cytometry, which confirmed that the NAP signal was specific to acti-
vated neutrophils compared to peripheral blood mononuclear cells and quiescent neutrophils (Supplementary 
Fig. S3).
NAP dequenching is rapid and sustained. When isolated healthy human neutrophils, primed with 
Cytochalasin B (10.4  µM), were exposed to the chemotactic peptide N-Formyl-Met–Leu–Phe-OH (fMLF) 
(500 nM) in order to induce calcium mediated degranulation, the appearance of intracellular punctate fluo-
rescence occurred rapidly, reaching a peak within two minutes and being sustained for at least one hour. This 
intracellular fluorescent signal was abrogated by co-incubation with Sivelestat (100 µM) (Fig. 2B,C and Sup-
plementary video S1).
NAP signal is dependent on dynamin-dependent internalization, HNE activity and alkalini-
sation of the neutrophil phagosome. Intracellular fluorescent green signal was quantified using flow 
cytometry. In the presence of A23187 (10 µM) there was a 50-fold increase in intracellular fluorescent signal 
Figure 2.  NAP selectively identifies activated neutrophils. (A) Activated neutrophils take up NAP (green) 
to exhibit bright green intracellular punctate fluorescent signal. Cells were stained with the nucleic acid 
counterstain Syto 60 (magenta). Scale bar 10 µm. (B) Graph illustrating results of objective image analysis 
pooled from three separate experiments (mean + SD). Dots are mean (± SD). Black line—primed neutrophils 
activated with fMLF (500 nM) at t = 10 s. Magenta line—primed neutrophils in continued presence of Sivelestat 
100 µM, activated with fMLF (500 nM) at t = 10 s. Statistical analysis by 2-way ANOVA with Bonferroni’s 
correction, p = 0.0082 between conditions up to 9-min time point, 3 degrees of freedom, an exact multiplicity 
adjusted p value is given with the figure at t = 2 min for illustrative purposes. N = 3 (distinct samples) for 
fMLF condition, N = 2 (distinct samples) for Sivelestat condition. (C) Confocal microscopy images of human 
neutrophils activated using 500 nM fMLF shown at various time points in the presence of NAP (5 µM, green). 
Images are representative from three separate experiments. Scale bar 20 µm.
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amongst freshly isolated neutrophils (Fig. 3A; gating strategy shown in Fig. 3B) as compared to the threefold 
increased seen with free human neutrophil elastase (Fig. 1C). The intracellular fluorescent signal could be abro-
gated by concurrent dynamin inhibition (Dynasore Hydate), which inhibits pinocytosis. NADPH oxidase inhi-
bition (Diphenyleneiodonium, DPI) reduced the overall mean fluorescent intensity in keeping with the role of 
NADPH oxidase contributing to the progressive alkalinisation of the neutrophil vacuole following phagocytosis. 
The intracellular signal was also abrogated by co-culture with Sivelestat indicating a contribution from elastase 
activity to the intracellular fluorescent signal (Fig.  3A,C). The contribution of these processes to the libera-
tion of fluorescent signal was confirmed using confocal microscopy, with Cytochalasin B (10.4 µM) and fMLF 
(500 nM) used to activate neutrophils (Fig. 3D,E). When neutrophils phagocytosed opsonized fluorescent beads 
in the presence of NAP, the de-quenched fluorescent signal co-localized with the beads (Fig. 3F). Additionally, 
when neutrophils phagocytosed fluorescently labelled Pseudomonas aeruginosa, the de-quenched signal co-
localled with the bacteria (Supplemental fig. S4). Both these results indicate that intracellular probe dequench-
ing occurred within the phagosome.
NAP manufactured to GMP standard was chemically stable and non-toxic. Having demon-
strated that locally delivered microdoses of NAP coupled with OEM could detect activated neutrophils in vitro 
in  situ within minutes, we manufactured NAP to GMP standards and performed preclinical toxicology and 
chemical stability analysis. NAP did not cause red cell haemolysis or neutrophil necrosis (Supplemental Fig. S5). 
NAP was delivered via the trachea to rats in a Contract Research Organization Good Laboratory Practice (GLP) 
toxicology study at approximately 700 times the human dose. NAP (100 µg) was instilled and rats underwent 
necroscopy at 3 and 15 days after delivery. No local or distant organ toxicity was observed and there were no hae-
matological or other metabolic consequences (Covance Laboratories, Harrogate, UK). A GLP AMES mutagenic-
ity test using the microsuspension-modified method appropriate for early clinical development demonstrated 
no mutagenicity. Stability assessment (Department of Chemistry, University of Edinburgh) demonstrated that 
NAP drug substance (as a dry powder) was stable for up to 4 years and 8 months at – 20 °C and as drug product 
(in aqueous solution) was stable for up to 2 years when kept at room temperature (Supplementary Tables S1 and 
S2). The release specifications for NAP drug substance and drug product are shown in Supplementary tables S3 
and S4.
NAP permitted visualization of activated neutrophils in the alveoli in patients in an explora-
tory clinical study. Six healthy volunteers, six patients with bronchiectasis and three mechanically-ven-
tilated critically ill patients completed the study. There were no adverse reactions related to NAP administra-
tion (Supplementary Table S5). As expected there were no increases in punctate cellular signal seen after the 
intrapulmonary administration of NAP in the healthy volunteers (Supplementary Fig. S6). Amongst bronchiec-
tatic patients a range of fluorescent responses following the application of NAP were observed. Investigation of 
these patients provided the opportunity to obtain BALF after performing OEM with NAP. Using flow cytometry 
neutrophil activation status was inferred by measuring CD63 (membrane protein associated primary neutrophil 
 granules25) and CD11b (cell surface marker of adhesion associated with the process of activation). Variable cell 
surface marker up regulation was detected (Fig. 4). Laboratory confocal microscopy was also performed on 
lavage directly following nuclear staining, and in one case where neutrophils were CD11b/CD63 high, neutro-
phils containing green punctate fluorescent were observed. Two blinded adjudicators displayed fair concord-
ance when using a four-point ordinal scale to provide a subjective assessment of 26 separate OEM/NAP video 
sequences taken across the 11 study participants who received the full dose of NAP (Cohen’s Kappa 0.247 ± SE 
0.101), and their scores are shown in Fig. 4. Example video sequences can be viewed with Supplementary videos 
S2 and S3.
We then demonstrated that the procedure is feasible in MV patients in the complex and demanding environ-
ment of an intensive care unit (ICU). Still images before and after the administration of NAP in three MV patients 
are shown in Fig. 5. Some cells with intracellular punctate fluorescent signal are seen after the application of 
Figure 3.  (A) Mean fluorescence index of entire granulocyte population as determined by flow cytometry. 
Quiescent (spotted bar), activated (white bar) and inhibited (grey bars) conditions are shown. Plots and images 
are representative from three independent experiments. Graph shows mean (± SEM) from three independent 
experiments. Statistical analysis by one-way ANOVA with Bonferroni’s correction, F = 73.80, DF = 12, exact 
multiplicity adjusted P value for each comparison shown in the graph. (B) Example flow plot of freshly isolated 
healthy human PMNs. Target population and percentage of parent gate shown (inset: parent gate). (C) Example 
histograms of de-quenched intracellular NAP fluorescence amongst forwarded PMNs are shown with key. 
The addition of each inhibitor partially returns the fluorescent intensity back towards the quiescent baseline. 
Plots are representative of three independent experiments. (D) Bar chart indicating the cellular fluorescence 
determined by objective image analysis in repeated field views across the incubation conditions. Results 
are mean (± SD). Statistical analyses determined by one-way ANOVA with post-hoc Bonferroni correction. 
F = 23.55, degrees of freedom 25, exact multiplicity corrected p value for each comparison shown. ns not 
significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Three fields of view from two independent 
experiments. (E) Example images of isolated neutrophils, primed with Cytochalasin B (10.4 µM), exposed to 
fMLF (500 nM) immediately after t = 0 s in the continued presence or absence of the various inhibitors as shown. 
(F) Fluorescent beads were opsonized and incubated with isolated healthy neutrophils in the presence of NAP. 
De-quenched green fluorescent signal co-localizes with the beads indicating the origin of intense fluorescence to 
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Figure 4.  Representative OEM images from participants with bronchiectasis before and after the application of NAP are shown in the 
left-hand image columns. One participant received NAP but did not tolerate subsequent imaging, so five sets of imaging are shown. 
Blue arrows—alveolar wall, red arrow—punctate fluorescent NAP signal, purple arrows—pulmonary capillary. The labelling of relevant 
features is not exhaustive in these representative images. Laboratory confocal microscopy from the broncho-alveolar lavage is shown 
with each pair of OEM images. Red stain—Calcein red cytoplasmic stain. Purple stain—Styo62 nuclear stain. Green stain—material 
excited at 488 nm and emitting at 500–530 nm. Calcein red and Syto62 are applied after lavage harvest. Green fluorescent staining 
has taken place within the lung. Left hand side: selected clinical parameters from each participant are shown. Right hand side: pooled 
subjective blinded video analysis from two blinded experienced observers working independently is shown. 1—no suspicion of NAP 
signal, 2—suspicion of NAP signal, 3—positive NAP signal, 4—very positive NAP signal. Of the  CD66bhi population in lavage, values 
for  CD11bhi and  CD63hi cell surface markers as a ratio of the relevant isotype control are shown. Bottom row; larger example OEM 
images for inspection, description given with image. Scale bar OEM 50 µm, scale bar laboratory confocal microscopy 50 µm.
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NAP (red arrows). However, punctate signal was seen prior to the application of NAP indicating the presence 
of auto-fluorescent cells undermining the discriminatory value of NAP unless comparison to baseline is made. 
In one participant auto-fluorescent fluid was observed (purple arrows) attributable to bilirubin which is known 
to fluoresce at this wavelength and this individual was jaundiced.
Figure 5.  OEM from three mechanically ventilated (MV) patients. Each pair of images are representative from 
an individual study participant. Blue arrows—alveolar wall, red arrow—punctate fluorescent NAP signal, yellow 
arrow—autofluorescent cell, purple arrow—bubble of fluorescent fluid. The labelling of relevant features is not 
exhaustive in these representative images.
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Discussion
Neutrophils are the first line of defense in the innate immune system. Neutrophil activation and response includes 
a wide range of orchestrated events including: migration to site of injury, rapid phagocytosis, release of destruc-
tive enzymes, and production of reactive oxygen species. Whilst these pathways bring about pathogen destruc-
tion, neutrophil activation is also implicated in the pathogenesis of many acute human diseases. Most of these 
phenotypic changes are dynamic and are not suitable for external static assessment following sample removal. 
Pathological evaluation of biopsied tissue aids the classification of diffuse inflammatory parenchymal lung dis-
eases. However, the lack of repeatability, small biopsy volume, and the static nature of the samples are potential 
limitations which support the development of more dynamic approaches to augment pathological sampling.
In contrast, real-time in situ characterization presents an opportunity to understand the contribution 
of neutrophil activation in patients with disease and stratify patients according to biological process rather 
than clinical phenotype. There is emerging evidence that neutrophil activation and migration from the cir-
culation occur  simultaneously26–28, but this has not been characterized in acutely unwell patients or exploited 
for clinical purposes. To date, in vivo neutrophil-specific molecular imaging has been limited to extraneously 
labeled  neutrophils29 or the use of  [18F]-fluorodeoxyglucose as a surrogate of inflammatory cell metabolic burst 
 activity27,28,30. Optical imaging has been used extensively for pre-clinical imaging of various aspects of neutrophil 
activation with a particular focus on enzymatic imaging, but no technique has been deployed for clinical use.
We developed an activated-neutrophil phenotype-specific imaging agent for application directly into human 
lungs for read out using optical endomicroscopy. We exploited three biochemical processes unique to acti-
vated neutrophils namely dynamin dependent endocytosis, phagosome alkalinization and elastase release and 
chemically modified a previously reported  compound23, with the intention of translating into human disease via 
endomicroscopy. In its resting state the three fluorescein moieties are quenched internally. The multibranched 
scaffold exploits the propensity of professional phagocytes to endocytose large  molecules31, a process dependent 
upon the action of dynamin, a GTPase that separates newly formed vesicles from the cellular  membrane32. Whilst 
dynamin is ubiquitous to eukaryotic cells, relying on dynamin-dependent endocytosis to rapidly concentrate 
NAP in the intracellular environment is the first step in targeting neutrophil activation. Unlike other profes-
sional phagocytes, where acidification of the phagosome is used as a mechanism for the destruction of ingested 
material, the neutrophil vacuole undergoes initial  alkalinization33. This process is brought about by the activity 
of the vacuolar membrane protein NADPH oxidase, which facilitates depolarization of the vacuolar membrane, 
flooding the vacuole with electrons used in the generation of oxygen super-radicals34. Protons are consumed 
through dismutation of radicals and the pH  rises35. This pH rise is more than just an unintended sequitur of 
the production of reactive oxygen species; it plays a role in the activity of HNE. HNE is normally sequestered 
in primary granules within the cytoplasm of quiescent neutrophils. It is released in the extracellular milieu and 
into phagosomes containing ingested  material36,37. It has a higher activity at pH 9 than at neutral pH, making 
it more destructive within the phagosome, and less destructive outside, limiting damage to host  tissue38. Segal 
first demonstrated the alkalization of the neutrophil vacuole by using fluorescein conjugated to Staphylococcus 
aureus33, and thus we use the same pH sensitive fluorophore on our SmartProbe. Consequently, we observe 
a partial abrogation of fluorescent signal when alkalization of the vacuole is inhibited, rather than complete 
abrogation, because fluorescein is still fluorescent at neutral pH. Each fluorescein moiety on our SmartProbe is 
connected through a polyethylene glycol chain to the amino-acid sequence EEINleRR. In the presence of HNE, 
the sequence is hydrolyzed, internal quenching is liberated and fluorescence increases. Through selective inhibi-
tion of these three processes, we demonstrate that NAP identifies an activated neutrophil phenotype according 
to the postulated mechanisms. The three pathways that we investigated as contributors (pinocytosis, alkalinisa-
tion, elastase) to probe activation in vitro, may be further dissected by dose–response experiments and/or by 
using different combinations of NADPH oxidase inhibitors and ROS scavengers or neutrophils from patients 
with chronic granulomatous disease (CGD). However, it is highly likely that these pathways are inseparable in 
the clinical environment and are unlikely to correlate with the clinical findings. The peptide sequence confers 
the ability of the SmartProbe to act as HNE sensor in isolation but in this capacity the performance is indeed 
limited. The signal-to-noise ratio of the SmartProbe is low in the extracellular environment where dequenching 
only occurs due to action of HNE, of the order of 3 to 1, and takes many minutes to reach maximal fluorescence. 
Existing HNE probes exhibit similar or superior performance in this  regard18,39 and have been deployed for 
in vivo fluorescent surface imaging of HNE activity, albeit limited to small animal work. However, in the complex 
intracellular environment the signal of our probe is very bright, with a signal-to-noise ratio of approximately 50 
to 1, with peak fluorescence generated within two minutes of neutrophil activation, and thus an ideal profile to 
identify activated neutrophils after the local delivery of a SmartProbe into the distal lung.
So far, few molecular imaging strategies have been translated to human studies. Hurdles of cost of develop-
ment, cumbersome equipment, and the use of ionising radiation have hindered development of nuclear modali-
ties such as positron-emission tomography (PET). Optical molecular imaging employs wavelengths of the elec-
tromagnetic spectrum that do not require ionising radiation and are relatively low  cost40. Visible wavelengths of 
light exhibit a lack of tissue penetration (at most a few millimetres), which has been a limitation for human organ 
imaging, but the use of fibre-based approaches, such as OEM, may represent a solution by allowing microscopy 
of any endoscopically-accessible organ system. We recently demonstrated the capability of the optical imaging/
SmartProbe strategy to detect bacteria in the lungs of critically ill patients, with applicability to patients with 
severe community acquired and ventilator-associated  pneumonia19. In order to proceed to human study, we 
adopted a microdosing approach, whereby each single application of an active pharmaceutical ingredient does 
not exceed 100 µg, with the inherent safety advantages this provides. NAP was non-toxic and chemically robust 
with over four years of stability demonstrated for the dry drug substance and two years for the aqueous drug 
product (drug substance dissolved in phosphate buffered saline). After completing a Phase 1 healthy volunteer 
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study, we demonstrated the punctate signal of activated neutrophils in a subset of patients with bronchiectasis, 
giving imaging characteristics similar to those observed in vitro. Even amongst a small number of patients 
chronically unwell with bronchiectasis, we observed heterogeneity of neutrophil activity. There was no obvious 
routinely available clinical information that predicted the occurrence of a positive NAP signal, strengthening the 
case for the development of such translational tools in clinical practice in order to interrogate patient-specific 
biological processes in ways not available with traditional systemic assessments. The demonstrated coupling of 
bespoke optical molecular imaging probes (SmartProbes) and OEM can readily be added to standard broncho-
scopic assessments, making the approach particularly suitable in the surveillance and diagnosis of patients with 
acute lung inflammation requiring MV, and so we progressed to demonstrate the safety and feasibility of such 
an approach in three MV patients.
There are some acknowledged limitations to the current work. The imaging agent is designed to optimally 
absorb light of 480 nm wavelength and emit above 520 nm, a design implicit upon the single-wavelength OEM 
devices that are clinically certified for use at this time. The use of fluorescein is a pre-requisite at this stage, due to 
the pH-dependent fluorescence and the vast historical safety record in human application. This leads to significant 
overlap with endogenous green autofluorescent signal from connective tissue in the lung and potential challenges 
to confidently identify the optical signal in the complex in vivo microenvironment. In addition, there is a lack 
of robust objective image analysis hampered in part by the complex nature of image that is constructed, the lack 
of immediately discriminant features such as colour, and a lack of data on which to train an objective analysis 
algorithm. Other limitations are more fundamental: in comparison to routine laboratory assessments, the varied 
origin of probe dequenching and the variable dose that may reach the alveolus could be criticized for lacking 
precision, but the lungs of sick patients are not fully represented by the controlled samples of the laboratory. 
Here, some precision has necessarily been pragmatically sacrificed in order to interrogate a biological process 
that has not previously been documented in vivo in situ in humans. At this stage of development, our current 
work does not demonstrate the utility of this imaging technique for patient stratification. For example, in the 
critically ill, stratification of patients by alveolar neutrophil activation is hypothetical, due to the current poor 
understanding of in vivo in situ pathology in humans and the consequent lack of proven biological therapies. 
Indeed, critically ill patients displaying a heterogeneity of diseases and disease severities are difficult to study, 
and there are currently few acceptable disease reference standards. However, the very lack of these reference 
standards supports the development of novel methodologies to specifically incorporate biological process into 
the diagnosis and stratification of disease.
In summary, we report the development and initial experience of an optical molecular imaging approach 
capable of rapidly identifying activated neutrophils in the human alveolar space that can be applied at the bedside 
and yield immediate biological data. In a Phase 0/1 clinical trial of the investigational medicinal product, we 
demonstrated that NAP coupled with OEM is safe, well tolerated, shows promising imaging characteristics, and 
is the first demonstration of in vivo microscopic imaging of neutrophil activity in humans with lung disease. No 
firm conclusions can yet be drawn regarding the ultimate utility of the technique. To that end, a phase 2 study 
has begun to evaluate the reliability and validity of this novel technique to quantify neutrophil activation, predict 
outcome and stratify MV patients in the intensive care unit. (Sensing using the Neutrophil Activation Probe on 
the Intensive Therapy unit, SNAP-IT, NCT: 02804854 EudraCT: 2015-005676-25).
Methods
Ethics statement. All experiments using human volunteers were performed following approval from the 
appropriate regional ethics committee (REC) and informed consent was obtained from each participant or their 
personal legal representative for adults with incapacity (in accordance with the Adults with Incapacity (Scotland) 
Act 2000). BALF for alveolar macrophages: (East of Scotland Research Ethics Committee 1 no: 07/S1102/20), 
blood for assessment of leucocyte populations (Lothian Research Ethics Committee no: 08/S1103/38), and first-
in-human assessment of probe performance and safety (Scotland A Research Ethics Committee no: 12/SS/0004, 
EudraCT 2011-006169-17, NCT01532024). All methods were performed in accordance with the relevant guide-
lines and regulations. Animal toxicology was conducted in compliance with UK Good Laboratory Practice 
Regulations by a third party contract research organization (Covance Laboratories Ltd, Harrogate, UK) under 
Covance UK Home Office License for toxicology. All procedures were approved by and performed in accordance 
with Institutional Committees on Animal Welfare of the UK Home Office in compliance with The Home Office 
Animals Scientific Procedures Act, 1986 (Project licence number 70/7602-1). All procedures were carried out 
by a personal licence holder.
Chemical synthesis of NAP. The synthetic route to manufacture NAP is shown in Fig. 6. The dendrimer 
scaffold 123 is linked to a solid support to permit further conjugation. The peptide sequence (–Glu–Glu–Ile–Nle–
Arg–Arg–) is built and a solubilizing moiety (PEG) is added along with the fluorescent dye, carboxyfluorescein. 
NAP is then released from the solid support followed by a purification step.
Synthesis of resin-bound dendrimeric scaffold (3). Resin 2 was synthesized using a 
4-[(2,4-dimethoxyphenyl)-(Fmoc-amino)methyl]phenoxyacetic acid (Rink amide linker) attached to amino-
methyl PS resin (1% DVB, 100–200 mesh, 1.43 mmol/g capacity). Thus Fmoc-Rink-amide linker (3 eq) was 
dissolved in DMF and Oxyma (3 eq) was added and the mixture was stirred for 10 min. DIC (3 eq) was then 
added and the resulting mixture was stirred for further 5 min. The solution was added to aminomethyl poly-
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Fmoc—deprotection. To the resin (pre-swollen in DCM) was added 20% piperidine in DMF and the reac-
tion mixture was shaken for 10 min. The solution was then drained, and the resin was washed with DMF (3×), 
DCM (3×) and MeOH (3×). This procedure repeated twice.
Isocyanate coupling. To resin 2 (1 g, 1 eq), pre-swollen in DCM (10 mL), was added a solution of isocy-
anate  monomer23 1 (5 g, 3.0 eq), DIPEA (3.0 eq) and DMAP (0.6 eq) in a mixture of DCM/DMF (1:1, 20 mL) 
and the mixture was shaken for 16 h and the reaction monitored by a quantitative ninhydrin  test41. The solution 
was drained, and the resin was washed with DMF (3×), DCM (3×) and MeOH (3×).
Dde—deprotection. To the resin (1 g), pre-swollen in DCM, was added 2% hydrazine in DMF (20 mL) and 
the reaction mixture was shaken for 2 h. The solution was then drained and the resin 3 was washed with DMF 
(3 × 20 mL), DCM (3 × 20 mL) and MeOH (3 × 20 mL).
Peptide, PEG and dye coupling for dendrimer (4). A solution of the appropriate Fmoc-amino acid 
(10 eq) (Fmoc-Arg(Pbf)-OH, Fmoc-Nle-OH, Fmoc-Ile-OH, Fmoc-Glu(tBu)-OH, Fmoc-PEG-OH, 5-carboxy-
fluorescein) and Oxyma (10 eq) in DMF was stirred for 10 min (with 3 eq of acid per amine at 0.1 M concentra-
tion). DIC (10 eq) was then added and the resulting solution was stirred for further 5 min. The solution was then 
added to resin 3 (1 eq), pre-swollen in DCM, and the reaction mixture was shaken for 0.5 h. The solution was 
drained, and the resin was washed with DMF (× 3), DCM (× 3) and MeOH (× 3). The coupling reactions were 
monitored by a quantitative ninhydrin  test41. Before the final cleavage, the resin was washed with 20% piperidine 
to remove any fluorescein phenol  esters42.
TFA cleavage and purification of NAP. The resin 4 (initial weight 1.5  g), pre-swollen in DCM, was 
treated with a cleavage cocktail of TFA/TIS/water (90/5/5) for 2 h at room temperature. The solution was drained 
and the resin was washed with 50% TFA/DCM solution. The peptide was precipitated by ether. The precip-
itated solid was collected by centrifugation and the solvent removed by decantation and the precipitate was 
washed with cold ether (3×). The peptide was dried in vacuum at ambient temperature for 6 h to give crude 
output of 5.7 g. The precipitate was then purified by reverse phase preparative HPLC and the required fractions 
were pooled and lyophilized to afford NAP as an orange odorless powder (1.4 g). HPLC (220 nm): tR = 3.4 min, 
Figure 6.  Synthesis of NAP.
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purity > 99%; Res. Sol: acetonitrile not detected by GC–MS; MALDI: C197H277N44O61: [M + H+] calculated: 
4236.88, [M + H+] found: 4236.02.
Plate reader assessment of probe de-quenching. To generate an emission spectrum, NAP was excited 
at 430 nm to ensure the spectrum could be visualized to the x-axis. Excitation/absorbance spectra were obtained 
with NAP diluted to 5 µM in PBS or freshly prepared pH buffer. Purified HNE (Elastin Products Company, 
MO, USA) and purified proteinase 3 (Sigma-Aldrich, Poole, UK) were made up according to the manufacturer’s 
instructions to yield appropriate stock concentrations. Stock preparations of purified enzyme were prepared 
according to manufacturers’ instructions and subsequently diluted appropriately with Phosphate Buffered Saline 
(PBS, Thermoscientific, MA, USA) and NAP to achieve a final volume of 200 µL per condition and a final NAP 
concentration of 5 µM. Solutions were prepared directly into 96 well plates (Corning, NY, USA) on ice, with or 
without the human neutrophil elastase inhibitor Sivelestat (ONO-5046, 100 µM, Tocris, Bristol, UK). Plates were 
subsequently incubated at 37 °C with fluorescent parameters recorded every minute for 1 h (Fig. 1C, excitation 
488 nm, emission 525 nm). All fluorescence parameters were recorded using a microplate reader (Synergy H1 
hybrid reader, BioTek, Potton, UK,).
Leucocyte isolation. Whole blood was obtained from peripheral venepuncture of healthy volunteers using 
a 19-gauge hollow needle and anticoagulated immediately. Polymorphonuclear cells (PMNs) and peripheral 
blood mononuclear cells (PBMCs) were isolated as previously  described43. For mixed leucocyte populations the 
neutrophil isolation procedure was arrested after dextran sedimentation of erythrocytes before the separation 
of PMNs and PBMCs. Leucocytes were suspended at the concentrations specified below in PBS with divalent 
cations for 30 min prior to any further experimentation. All cell counting was performed using an automated 
cell counter (Nucleocounter NC-100, Chemotec, Allerød, Denmark).
Lavage preparation. Following broncho-alveolar lavage samples were passed through to a 40  µM cell 
strainer to eliminate mucus and other debris. Cells were centrifuged as previously described and reconstituted 
in PBS with  Ca2+/Mg2+ at a concentration of 1 × 106/mL. The supernatant underwent fluorescent plate reader 
analysis to confirm that lavage had been taken from segments also exposed to NAP (data not shown).
Confocal imaging. Where stated commercial stains were used in accordance with the manufacturer’s 
instructions or applied to a suspension of the relevant cells in eppendorfs at a concentration of 1:1000 from 
delivered stock for 10 min at 37 °C and 500 rpm using an orbital plate shaker before undergoing one wash in 
PBS without divalent cations as described above. 8 well Lab-Tek II confocal chambers (VWR, PA, USA) were 
coated in fibronectin (1 µg/ml, Sigma-Aldrich) for 10 min at 37 °C. Wells were then washed twice before the 
addition of the appropriate cell suspension. Cells were typically seeded at a concentration of 0.5—1 × 106/mL. 
Cells were allowed to seed for 20 min at 37 °C after which the remaining supernatant was washed once using 
PBS without divalent cations. Where used, 200 µL of NAP (5 µM) was then applied to each well and imaging 
proceeded. For time course experiments PMNs were exposed to Cytochalasin B (10.4 µM) during seeding and 
fMLF (500 nM) after the initiation of time course imaging. Fluorescent beads (Micro particles based on mela-
mine resin, carboxylate-modified, nile blue-marked size: 6 μm, Sigma-Aldrich) were opsonised before being 
added directly to adherent neutrophils. Pseudomonas aeruginosa, at one optical density, were labelled with PKH 
(CellVue claret far red fluorescent cell linker kits, Sigma-Aldrich) according to the manufacturer’s instructions 
and added to adherent neutrophils. Incubation proceeded for 30 min at 37 °C prior to the addition of Calcein-
AM red–orange cytoplasmic dye (500 nM, Life technologies). Following a single wash with PBS, NAP was added 
to a final concentration of 5 µM. Imaging proceeded within 10 min.
A laser scanning confocal imaging system (LSM510; Carl Zeiss, Jena, Germany), incorporating an upright 
Axioskop FS2 microscope (× 63 objective) was used for image acquisition. 488 nm laser power was limited to 
5% of maximum to minimize phototoxicity. Fluorescein based dyes were excited with a dedicated 488 nm laser 
line, with emitted light detected at 500–530 nm. Syto 82 nuclear, calcein cytoplasmic dyes and CellMask Orange 
plasma membrane stain (all Invitrogen, Thermoscientific) were excited with a dedicated 543 nm line, with emitted 
light detected at 560–600 nm. Syto 60 (Invitrogen, Thermoscientific) stain was excited with a dedicated 633 nm 
line, with emitted light detected at 650–680 nm. PKH labelled bacteria were excited with a dedicated 633 nm 
line with emitted light detected at 650–705 nm. Detector gain and offset were adjusted with each use to achieve 
the highest dynamic range with smallest saturation.
Image analysis of laboratory confocal images. Image analysis was carried out using Fiji (version 
2.0.0). An algorithm was developed to calculate the area of each image taken up by intracellular punctate fluo-
rescence as a fraction of the area of the image taken up by cells. The Trainable Weka Segmentation plugin (v3.1.0) 
was used to differentiate cells from background. To calculate the numerator each image was filtered using a 
default threshold to eliminate all but intracellular fluorescent signal. Particle analysis of the resulting binary 
mask was used to calculate the appropriate number of pixels. Isolated healthy quiescent neutrophils from each 
experimental replication were taken as a baseline, and quantification of fluorescent signal is expressed in arbi-
trary units as a ratio of the corresponding baseline.
Flow cytometric evaluation. Neutrophils were suspended in PBS with divalent cations at a concentra-
tion of 10 × 106/mL. 0.85 × 106 /mL neutrophils were incubated in a final volume of 100 µL in 2 mL microtubes 
(Eppendorf, Hamburg, Germany) with or without the following pharmacological agents: A23187 (Calcium 
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Ionophore, 10 µM, Sigma-Aldrich), Dynasore Hydrate (30 µM, Sigma-Aldrich), Diphenyleneiodonium (DPI, 
10 µM, Sigma-Aldrich), Sivelestat (100 µM, Tocris). Incubation took place at 37 °C for 30 min and samples 
were shaken at 500 rpm using an orbital plate shaker (Thermomixer comfort, Eppendorf, Hamburg, Germany). 
Suspensions were then incubated with anti-human CD11b-APC (1:100 dilution, Clone ICRF44, Biolegend, CA, 
USA) at 22 °C for 30 min at 500 rpm before the application of NAP to a final concentration of 5 µM for 15 min 
at 22 °C and 500 rpm. Cells were washed in PBS without divalent cations at 350 g for 5 min at room temperature 
using a microtube centrifuge (Biofuge fresco, Heraeus, Hanau, Germany) and reconstituted in 175 µL PBS with-
out divalent cations. Samples were loaded onto a 96 round-bottomed well plate (Corning).
For the demonstration of NAP specificity to PMNs, a mixed leucocyte population was prepared as above 
and suspended in PBS with divalent cations at a cellular concentration of 10 × 106/mL. Where appropriate, sam-
ples were activated with A23187 (Calcium Ionophore, 1 µM) for 30 min at 37 °C and 500 rpm using an orbital 
plate shaker. 100 µL of prepared suspension was mixed with 100 µL of flow cytometry staining buffer solution 
(eBioscience, CA, USA) and then samples were incubated for 30 min at 22 °C and 500 rpm in the presence of 
anti-human CD45-PE (1:100 dilution, Clone HI30, Becton–Dickinson) and anti-human CD66b-AF647 (1:100 
dilution, Clone G10F5, Becton–Dickinson). NAP was then added to achieve a final concentration of 5 µM and 
microtubes were incubated at 22 °C and 500 rpm for a further 15 min. Samples were washed, reconstituted and 
loaded as above. The flow cytometry gating strategy shown in Supplementary Fig. S3B.
For the assessment of lavage samples, 100 µL of cell suspension was mixed with 100 µL of flow staining 
buffer (eBioscience, 00–4222-26) and CD66b-PE (1:50 dilution, Clone G10F5, Becton–Dickinson), CD63-PE/
Cy7 (1:50 dilution, Clone H5C6, Becton–Dickinson), CD11b-APC (1:50 dilution). Fluorescence minus one 
plus isotype (FMO-I) controls were included for each fluorescent parameter. Cell suspensions were incubated 
at 4 °C for 30 min using an orbital plate shaker. Cells were washed once into PBS without cations. Lavage PMNs 
were identified by the  CD66hi status. Fluorescent intensity from each compensated parameter was expressed as 
a function of the relevant FMO-I control for each patient (Supplementary Fig. S7).
Flow cytometry was performed using an Accuri C6 flow cytometer and BD CSampler software (both Bec-
ton–Dickinson, NJ, USA). Compensation beads and single stain controls were used where appropriate. On one 
occasion, due to technical malfunction, a BD Calibur flow cytometer using BD CellQuest Pro software was used 
to analyse lavage samples. The cytometer was thresholded on forward scatter to eliminate debris. The cytom-
eter was aligned monthly using Calibrite 3, APC and 8 peak beads (Becton–Dickinson) to calibrate scatter and 
fluorescence parameters.
Data analyses were performed using Flowjo v10.0.8r1 (Treestar, Ashland, OR, USA). Samples were repeated in 
duplicate for each individual donor and pooled to yield a point estimate for each condition and each donor. The 
point estimates from different donors were pooled to yield an overall mean point estimate for each condition ± SE.
Cellular toxicity. Membrane toxicity of NAP was assessed using erythrocyte haemolysis. Isolated erythro-
cytes remaining after leukocyte separation were diluted 1:5 with PBS without cations and 50 µL of this red cell 
suspension was added to wells of a 96-well plate. Working concentration of NAP (5 µM), or working concentra-
tion × 2, was added to the relevant well. Positive control wells contained Triton X-100 (0.4%, Sigma-Aldrich) 
and negative control wells contained PBS w/o only. The 96-well plate was incubated for one hour at 37 °C in a 
humidified environment. Following incubation, 180 µL of PBS without cations was added to each well and the 
plate was centrifuged at 2500 rpm for 10 min. 100 µL of supernatant from each well was removed and aliquoted 
into clean wells. Absorbance at 350 nm was recorded using a plate reader. Triplicate repeats were pooled to yield 
an overall mean point estimate ± SEM of haemolysis that was expressed as a percentage of the positive control. 
For neutrophil toxicity freshly isolated human peripheral neutrophils were resuspended at 10 × 106 cells/mL in 
IMDM with 10% autologous serum and cultured for 18hrs ± 5 µM NAP at 37 degrees in a 5%  CO2 incubator. As 
a positive control for death, neutrophils were snap frozen on dry ice prior to thawing in hot water. Neutrophils 
were dislodged via pipetting, and 40 µL transferred into flow tubes containing Annexin V (1:1000) in Annexin 
V binding buffer (HBSS + calcium + magnesium containing 5 mM Calcium chloride) and incubated on ice for 
10 min. Immediately prior to flow cytometry (5L Fortessa, BD) 1 µL propidium iodide (from 100ug/mL stock) 
was added. Duplicate repeats were pooled to yield an overall mean point estimate ± SEM of apoptosis and necro-
sis that was expressed as a percentage of total cells.
Optical endomicroscopy. A commercially available 488 nm excitation CLE platform and 1.4 mm diam-
eter tip optical fibre was utilized (Cellvizio 488 with alveoflex fibre, Mauna Kea Technologies, Paris, France) 
along with the associated proprietary software (Image cell v3.8, Mauna Kea Technologies). Alveoscopy videos 
were acquired at 12 frames per second. For in-human investigations a clinically approved version of the Cellvizio 
488 laser-scanning unit (with associated clinically rated proprietary software) was used. Videos and still images 
were prepared for presentation using Cellvizio Viewer 1.6.2 (Mauna Kea Technologies). Videos were automati-
cally converted to gray-scale by the viewer software, so were false colored green-white to illustrate that the 
wavelengths being detected were predominantly in the green region of the visible spectrum. Where applicable, 
if two or more videos or stills were visually compared, the automatic software performing continuous auto-gain 
for optical dynamic range was disabled and gain was fixed.
Exploratory clinical study. The study was registered with the EudraCT database (EudraCT number: 2011-
066167-17) and with the National Clinical Trials database (NCT01532024). The primary objective was feasibil-
ity: could activated neutrophils within the alveolar space be detected with NAP and OEM over background 
autofluorescence. The secondary objective was safety: defined by the occurrence of adverse events. Six healthy 
male volunteers were recruited through study specific advertisements distributed via University of Edinburgh 
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mailing lists. Participants gave written acknowledgement of informed consent after receiving oral and written 
explanation of the study. Healthy volunteers attended the Edinburgh Clinical Research Facility within the Royal 
Infirmary of Edinburgh for all study specific events. After consent was provided potential participants were 
checked against the over-volunteering prevention system before undergoing medical screening. Participants’ 
general practitioners were asked to confirm the past medical history before volunteers were approved to par-
ticipate. Three ventilated male patients with pulmonary infiltrates on the intensive care unit were recruited after 
initial identification by the supervising medical and nursing team. The attending intensive care physician made 
an assessment of the capacity of each potential participant to make decisions about potential enrolment in the 
study. Those with capacity gave written acknowledgement of informed consent after receiving oral and written 
explanation of the study. For those without capacity, a personal legal representative (also known as guardian/
welfare attorney/nearest relative) gave written acknowledgement of informed consent after receiving oral and 
written explanation of the study. Participants’ general practitioners were informed of their participation in the 
study. If a participant enrolled by the consent of their personal legal representative subsequently regained capac-
ity they received a written explanation of the study. Six patients known to have bronchiectasis were recruited 
after initial identification by the supervising medical and nursing team. Participants gave written acknowledge-
ment of informed consent after receiving oral and written explanation of the study. A full description of inclu-
sion and exclusion criteria can be found in Supplementary table S6.
Testing in humans. The safety of ascending doses of NAP (5 µg × 2, 10 µg × 2 and 80 µg × 2) was assessed 
in healthy volunteers. Each participant received only one dose of NAP, with the maximum dose within the 
microdosing limits set out by the European Medicines Agency (ICH Topic M3 (R2)). NAP was always delivered 
directly to the deep lung. Healthy volunteers were offered non-sedated bronchoscopy or received intravenous 
midazolam and alfentanil. Topical local anaesthesia (Lidocaine) was applied to the nasopharynx and flexible 
fibre-optic bronchoscopy proceeded per nasum or per orum. The bronchoscope was wedged in the right mid-
dle lobe (and additionally the right lower lobe for participants receiving 80 µg of NAP). NAP was administered 
via flexible catheter (1.5 mm APC catheter, ERBE, GA, USA) to the distal part of the lung in each lobe visited. 
OEM recording took place before and after the delivery of NAP. An independent data monitoring and safety 
committee reviewed all available clinical and laboratory information before providing permission to proceed 
with the next participant and also gave explicit permission to proceed to the Intensive Care Unit. Healthy vol-
unteers remained in the Edinburgh Clinical Research Facility for 24 h after the administration of NAP for the 
purposes of clinical, radiological and laboratory monitoring and received a telephone follow-up phone call 72 h 
after the administration of NAP to enquire about the development of any symptoms that could have constituted 
an adverse event. Ventilated patients on the intensive care unit underwent chest x-ray to determine the most 
appropriate lobes to assess. For the procedure, patients received adequate sedation and analgesia, typically via 
the intravenous infusion of propofol and alfentanil. A physician provided peri-procedural anaesthesia for the 
patient. A bronchoscope was passed through the endotracheal tube to the pre-determined lobes. Otherwise, 
the administration of NAP and the alveoscopy imaging procedure were identical to the healthy volunteer study. 
Clinical, radiological and laboratory monitoring took place on the intensive care unit and each patient was 
reviewed thoroughly at 24 and 72 h after dosing to determine if any adverse events had occurred. Patients with 
bronchiectasis underwent sedated bronchoscopy. Lobes for investigation were selected by interrogation of avail-
able radiological imaging. If possible, a non-diseased lung segment was selected as a control. The delivery of 
NAP and imaging proceeded as per the healthy volunteer portion of the study, except where patients indicated 
discomfort or intolerance of the procedure, in which case the procedure was abbreviated at the discretion of the 
endoscopist. The initial imaging dose was always 24 µg per lobe, and the total delivered dose was always 80 µg. If 
participants were recruited from the bronchiectasis out patient clinic, they were followed up for 4 h in the dedi-
cated medical day case unit. Discharge occurred on the basis of satisfactory observations and post-procedure 
chest x-ray appearances, and if standard medical day case unit discharge criteria were met. Participants were 
followed up by telephone at 24 h and 72 h. If participants were current in-patients on the respiratory ward, they 
returned there after bronchoscopy. They received the same follow-up but responsibility for other treatments and 
decisions returned to the attending clinical team.
Human safety monitoring. For the purposes of screening, safety surveillance the following venous blood 
and urine samples were acquired. Haematology: haemoglobin, white cell count and platelet count. Biochemistry: 
sodium, potassium, urea, creatinine, bilirubin, ALT, glucose and C-reactive protein. Blood samples were ana-
lysed by the clinical laboratories of the Royal Infirmary of Edinburgh. Urinary drug screen: cocaine, ampheta-
mines, morphine, benzodiazepines, methadone and THC (healthy volunteers only). The following additional 
safety measurements were performed. Vital signs: Blood pressure (Omron 705 BP machine), heart rate, pulse 
oximetry (Mindray, Shenzhen, China) temperature (Genius 2 IR Tympanic Thermometer, Covidien, Dublin, 
Republic of Ireland) and respiratory rate. Electrocardiogram: 12 lead (Mac 1200, GE Healthcare, Buckingham-
shire, UK). Spirometry:  FEV1, FVC and  FEV1:FVC ratio (Alpha, Vitalograph, Buckingham, UK, healthy volun-
teers only). Chest X-ray: trial physician interpretation. Arterial blood gas analysis:  PaO2,  PaCO2,  [H+],  [HCO3−] 
and base excess (intensive care patients only, Rapidlab 1265, Siemens, Munich, Germany). Ventilatory param-
eters: Mode of ventilation, positive end expiratory pressure, ventilatory frequency (total and mandatory), tidal 
volume, and minute ventilation (intensive care patients only, Infinity C500 or Evita XL, Dräger). The schedule of 
study specific investigations can be found in the Supplementary material (Supplementary Tables S7, S8, and S9).
Statistical analysis. Statistical analyses are described with each result. All statistical analyses were per-
formed in Prism v6 (GraphPad Software, CA, USA), except Kappa statistics, which were calculated using the 
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GraphPad online calculator, located at https ://graph pad.com/quick calcs /kappa 1.cfm. An independent statisti-
cian confirmed that no statistical analyses were required to achieve the objectives of the exploratory clinical 
study.
 Data availability
Data are available from the corresponding author upon reasonable request.
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